Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study

Area of Science:

• Gastroenterology
• Hematology
• Pharmacology

Background:

• Massive upper gastrointestinal hemorrhage presents a significant clinical challenge with high morbidity and mortality.
• Effective management strategies are crucial to reduce bleeding, transfusion requirements, and surgical interventions.

Purpose of the Study:

• To evaluate the efficacy of tranexamic acid in patients experiencing massive upper gastrointestinal hemorrhage.
• To assess the impact of tranexamic acid on transfusion needs, operative rates, and mortality.

Main Methods:

• A double-blind, placebo-controlled trial involving 149 patients with massive upper gastrointestinal hemorrhage.
• Patients received either tranexamic acid (1 g IV six times daily, then 1.5 g PO four times daily) or placebo.
• Demographic and clinical data, transfusion requirements, and operative and mortality rates were recorded.

Main Results:

• The tranexamic acid group required significantly less blood transfusion, particularly on the second day post-admission.
• Fewer patients in the tranexamic acid group underwent surgery compared to the placebo group (10 vs. 18).
• Mortality rates were comparable between the groups (11 in the treatment group vs. 12 in the placebo group).

Conclusions:

• Tranexamic acid appears to have a beneficial, albeit small, effect in managing massive upper gastrointestinal hemorrhage.
• The drug may reduce the need for blood transfusions and surgical intervention in these patients.
• Further research may elucidate the optimal role and dosage of tranexamic acid in gastrointestinal bleeding.